Home
About
Overview
Sharing Data
ORCID
Help
History (2)
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Patient Portal Barriers and Group Differences: Cross-Sectional National Survey Study.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Patient Portal Barriers and Group Differences: Cross-Sectional National Survey Study.
Patient Portal Barriers and Group Differences: Cross-Sectional National Survey Study. J Med Internet Res. 2020 09 17; 22(9):e18870.
View in:
PubMed
subject areas
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Patient Portals
Surveys and Questionnaires
authors with profiles
Christopher Shea